Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

19 Aug 2024

Abstract excerpt

ABSTRACT: Multiple myeloma (MM) is an incurable malignancy characterized by altered expression of coding and noncoding genes promoting tumor growth and drug resistance. Although the crucial role of long noncoding RNAs (lncRNAs) in MM is clearly established, the function of the noncoding RNAome, which might allow the design of novel therapeutics, is largely unknown. We performed an unbiased CRISPR-Cas9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39158066
DOI: 10.1182/blood.2023021991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myelomaPMID 39158066Read ↗

The Multiple Myeloma Landscape: Epigenetics and Non-Coding RNAsSemantic proximity Read ↗

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myelomaSemantic proximity Read ↗

Long non‑coding RNAs in multiple myeloma (Review)Semantic proximity Read ↗

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.Semantic proximity Read ↗

Long Non-Coding RNAs in Multiple MyelomaSemantic proximity Read ↗

Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple MyelomaSemantic proximity Read ↗

Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myelomaSemantic proximity Read ↗

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaSemantic proximity Read ↗

CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network.Semantic proximity Read ↗

Identification of novel long noncoding RNA with distinct expression patterns in different subtypes of multiple myelomaSemantic proximity Read ↗

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.Semantic proximity Read ↗

The role of long non‐coding RNAs in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.